' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

Publikationen

Gewähltes Keyword: Hypofractionation


Hypofractionated Whole Breast Irradiation and Boost-IOERT in Early Stage Breast Cancer (HIOB): First Clinical Results of a Prospective Multicenter Trial (NCT01343459).
Fastner, G; Reitsamer, R; Gaisberger, C; Hitzl, W; Urbański, B; Murawa, D; Matuschek, C; Budach, W; Ciabattoni, A; Reiland, J; Molnar, M; Vidali, C; Schumacher, C; Sedlmayer, F; On Behalf Of The Hiob Trialist Group, ;
Cancers (Basel). 2022; 14(6):
Originalarbeiten (Zeitschrift)
Moderate hypofractionation remains the standard of care for whole-breast radiotherapy in breast cancer: Considerations regarding FAST and FAST-Forward.
Krug, D; Baumann, R; Combs, SE; Duma, MN; Dunst, J; Feyer, P; Fietkau, R; Haase, W; Harms, W; Hehr, T; Piroth, MD; Sedlmayer, F; Souchon, R; Strnad, V; Budach, W
STRAHLENTHER ONKOL. 2021; 197(4): 269-280.
Übersichtsarbeiten
Moderately hypofractionated radiotherapy as definitive treatment for localized prostate cancer: Pattern of practice in German-speaking countries : A survey of the Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and the Working Party on Radiation Oncology of the German Cancer Society (DKG-ARO).
Shelan, M; Aebersold, DM; Albrecht, C; Böhmer, D; Flentje, M; Ganswindt, U; Höcht, S; Hölscher, T; Müller, AC; Niehoff, P; Pinkawa, M; Schmidt-Hegemann, NS; Sedlmayer, F; Wolf, F; Zamboglou, C; Zips, D; Wiegel, T; Ghadjar, P;
Strahlenther Onkol. 2021; 197(11): 993-1000.
Originalarbeiten (Zeitschrift)
Ultrahypofractionation of localized prostate cancer : Statement from the DEGRO working group prostate cancer.
Wolf, F; Sedlmayer, F; Aebersold, D; Albrecht, C; Böhmer, D; Flentje, M; Ganswindt, U; Ghadjar, P; Höcht, S; Hölscher, T; Müller, AC; Niehoff, P; Pinkawa, M; Schmidt-Hegemann, NS; Zamboglou, C; Zips, D; Wiegel, T;
Strahlenther Onkol. 2021; 197(2): 89-96.
Übersichtsarbeiten
High-dose carbon-ion based radiotherapy of primary and recurrent sacrococcygeal chordomas: long-term clinical results of a single particle therapy center.
Bostel, T; Mattke, M; Nicolay, NH; Welzel, T; Wollschläger, D; Akbaba, S; Mayer, A; Sprave, T; Debus, J; Uhl, M;
Radiat Oncol. 2020; 15(1):206
Originalarbeiten (Zeitschrift)
Risk-adapted moderate hypofractionation of prostate cancer : A prospective analysis of acute toxicity, QOL and outcome in 221 patients.
Schörghofer, A; Groher, M; Karner, J; Kopp, A; Kametriser, G; Kunit, T; Holzinger, J; Sedlmayer, F; Wolf, F;
Strahlenther Onkol. 2019; 195(10):894-901
Originalarbeiten (Zeitschrift)
Hypofractionated radiotherapy for localized prostate cancer.
Höcht, S; Aebersold, DM; Albrecht, C; Böhmer, D; Flentje, M; Ganswindt, U; Hölscher, T; Martin, T; Sedlmayer, F; Wenz, F; Zips, D; Wiegel, T;
Strahlenther Onkol. 2017; 193(1): 1-12.
Übersichtsarbeiten
Intraoperative radiotherapy (IORT) as boost in breast cancer.
Sedlmayer, F; Reitsamer, R; Wenz, F; Sperk, E; Fussl, C; Kaiser, J; Ziegler, I; Zehentmayr, F; Deutschmann, H; Kopp, P; Fastner, G;
Radiat Oncol. 2017; 12(1): 23
Übersichtsarbeiten
Modern Radiotherapy Concepts and the Impact of Radiation on Immune Activation.
Deloch, L; Derer, A; Hartmann, J; Frey, B; Fietkau, R; Gaipl, US;
Front Oncol. 2016; 6:141
Übersichtsarbeiten
Comparison of two different rectal spacers in prostate cancer external beam radiotherapy in terms of rectal sparing and volume consistency.
Wolf, F; Gaisberger, C; Ziegler, I; Krenn, E; Scherer, P; Hruby, S; Schätz, T; Forstner, R; Holzinger, J; Vaszi, A; Kametriser, G; Steininger, P; Deutschmann, H; Sedlmayer, F;
Radiother Oncol. 2015; 116(2): 221-225.
Originalarbeiten (Zeitschrift)
Hypofractionated stereotactic radiotherapy of acoustic neuroma : Volume changes and hearing results after 89-month median follow-up.
Kranzinger, M; Zehentmayr, F; Fastner, G; Oberascher, G; Merz, F; Nairz, O; Rahim, H; Sedlmayer, F;
Strahlenther Onkol. 2014; 190(9): 798-805.
Originalarbeiten (Zeitschrift)
Evaluation of genome-wide loci of iron metabolism in hereditary hemochromatosis identifies PCSK7 as a host risk factor of liver cirrhosis.
Stickel, F; Buch, S; Zoller, H; Hultcrantz, R; Gallati, S; Osterreicher, C; Finkenstedt, A; Stadlmayr, A; Aigner, E; Sahinbegovic, E; Sarrazin, C; Schafmayer, C; Braun, F; Erhart, W; Nothnagel, M; Lerch, MM; Mayerle, J; Völzke, H; Schaller, A; Kratzer, W; Boehm, BO; Sipos, B; D"Amato, M; Torkvist, L; Stal, P; Arlt, A; Franke, A; Becker, T; Krawczak, M; Zwerina, J; Berg, T; Hinrichsen, H; Krones, E; Dejaco, C; Strasser, M; Datz, C; Hampe, J;
Hum Mol Genet. 2014; 23(14): 3883-3890.
Originalarbeiten (Zeitschrift)
Randomized phase II trial of hypofractionated proton versus carbon ion radiation therapy in patients with sacrococcygeal chordoma-the ISAC trial protocol.
Uhl, M; Edler, L; Jensen, AD; Habl, G; Oelmann, J; Röder, F; Jäckel, O; Debus, J; Herfarth, K;
Radiat Oncol. 2014; 9:100
Originalarbeiten (Zeitschrift)
DEGRO practical guidelines: radiotherapy of breast cancer I: radiotherapy following breast conserving therapy for invasive breast cancer.
Sedlmayer, F; Sautter-Bihl, ML; Budach, W; Dunst, J; Fastner, G; Feyer, P; Fietkau, R; Haase, W; Harms, W; Souchon, R; Wenz, F; Sauer, R;
Strahlenther Onkol. 2013; 189(10): 825-833.
Originalarbeiten (Zeitschrift)